Clinical Trial

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Study acronym: AG10
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-07-30; most recent amendment 2025-10-09.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-09-05
Status change: Not Yet Recruiting → Enrolling by Invitation 2022-03-21
Trial Details
NCT Number NCT04988386
Lead Sponsor Eidos Therapeutics, a BridgeBio company
Conditions Amyloid Cardiomyopathy, Transthyretin-Related
Enrollment 389 participants
Start Date 2021-10-27
Primary Completion 2028-04-15 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-14